Use of a licensed electrolyte solution as an alternative to tissue culture medium for bone marrow collection

Use of a licensed electrolyte solution as an alternative to tissue culture medium for bone marrow collection
复制标题

使用许可的电解质溶液作为骨髓采集的组织培养基的替代品

DOI:
--
复制
发表时间:
1993
期刊:
影响因子:
2.9
通讯作者:
R. Sacher
R. Sacher
中科院分区:
医学3区
文献类型:
--
作者:
E. Areman;S. Dickerson;P. L. Kotula;T. Spitzer;R. Sacher

文献摘要

参考文献

被引文献

相似文献

用于移植的骨髓传统上被收集到含有肝素的组织培养基中。在采集28例骨髓(17例自体骨髓和11例同种异体骨髓)时,使用许可的电解质溶液(Plasma‐ Lyte A [PLA])作为组织培养基的替代品,随后进行移植。从25例可评价患者中分析的数据包括移植骨髓中的细胞和集落形成单位数量以及中性粒细胞和血小板植入时间。将这些结果与采集到组织培养基(RPMI-1640 [RPMI])中的30个(26个可评价)先前移植骨髓中的结果进行比较。PLA组和RPMI组的自体骨髓移植患者在移植后平均19天达到中性粒细胞计数≥ 0.5 × 109/L。接受RPMI中收集的异基因骨髓移植的患者在移植后平均20天达到≥ 0.5 × 109/L的中性粒细胞,而接受PLA中收集的骨髓移植的患者在平均21天内达到中性粒细胞植入水平。由于本研究中RPMI和PLA的体外和体内结果相似,因此需要使用许可的溶液进行临床骨髓移植的进一步研究。
Bone marrow for transplantation is traditionally collected into tissue culture medium with heparin. A licensed electrolyte solution (Plasma‐ Lyte A [PLA]) was used as a substitute for tissue culture medium in the harvesting of 28 bone marrows, 17 autologous and 11 allogeneic, which were subsequently transplanted. Data that were analyzed from the 25 evaluable patients consisted of the numbers of cells and colony‐forming units in the transplanted marrow as well as the time to neutrophil and platelet engraftment. These results were compared with those in the 30 (26 evaluable) preceding transplanted marrows that were collected into a tissue culture medium (RPMI‐1640 [RPMI]). The autologous marrow transplant patients in both the PLA and RPMI groups reached a neutrophil count of > or = 0.5 × 109 per L a mean of 19 days following transplantation. The patients who underwent transplantation with allogeneic bone marrow collected in RPMI achieved > or = 0.5 × 109 per L of neutrophils an average of 20 days following transplantation, while those who received marrow collected in PLA achieved engraftment of neutrophils to that level in a mean of 21 days. Because in vitro and in vivo results with RPMI and PLA are similar in this study, further work using a licensed solution for clinical bone marrow transplantation is indicated.
DOI: --
发表时间: 1991
影响因子: 4.8
作者:
Rowley,SD;Piantadosi,S;Marcellus,DC;Jones,RJ;Davidson,NE;Davis,JM;Kennedy,J;Wiley,JM;Wingard,JR;Yeager,AM
通讯作者: Yeager,AM